After 14 days, bioluminescence imaging demonstrated that knockdown of YANK2 inhibited U87MG xenograft tumor growth (Fig. 2E left panel) and that overexpression of YANK2 promoted GL261 xenograft tumor growth (Fig. 2H left panel) in vivo. The gene discussed is STK32B; the disease is neoplasm.